12/21/22 9:00 AMNasdaq : ABMD clinical trialfda approvalFDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical TrialAbiomed announces the United States Food and Drug Administration has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support at Ascension St. John Hospital in Detroit, led the procedures. This single-arm,...RHEA-AIneutral
12/14/22 7:15 AMNYSE, Nasdaq : JNJ, ABMD Johnson & Johnson Announces Extension of Abiomed Tender Offer to December 21, 2022Johnson& Johnson, the world’ s largest, most diversified healthcare products company, today announced that Athos Merger Sub, Inc., a wholly owned subsidiary of Johnson& Johnson, has extended the expiration date of its offer to acquire all of the outstanding shares of common stock of Abiomed, Inc., for an upfront payment of $380.00 per share in cash, plus one...RHEA-AIneutral
12/05/22 8:03 AMNasdaq : ABMD First Patients in the World Treated with Impella RP Flex with SmartAssistAbiomed announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed’ s newest heart pump for patients experiencing right heart failure. The patients were treated at Hackensack University Medical Center/Hackensack Meridian Health in Hackensack, N.J., and Kingwood Medical Center in Kingwood, Texas.RHEA-AIpositive
11/01/22 7:00 AMNasdaq, NYSE : ABMD, JNJ Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over YearABIOMED, Inc., a leader in breakthrough heart, lung and kidney support technologies, today announces financial results for the quarter ended September 30, 2022. The company saw an improvement in patient utilization in August and September as the impact from these headwinds moderated. U.S. product revenue of $208 million, an increase of 10% on a reported basis....RHEA-AIpositive
11/01/22 6:30 AMNYSE, Nasdaq : JNJ, ABMD acquisitionJohnson & Johnson to Acquire AbiomedJohnson& Johnson, the world’ s largest, most diversified healthcare products company, and Abiomed, a world leader in breakthrough heart, lung and kidney support technologies, today announced that they have entered into a...RHEA-AIpositive
10/31/22 8:02 AMNasdaq : ABMD fda approvalImpella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart FailureAbiomed announces that Impella RP Flex with SmartAssist has received U.S. Food and Drug Administration pre-market approval, the FDA’ s highest level of approval, as safe and effective to treat acute right heart failure for up to 14 days. Impella RP Flex is implanted via the internal jugular vein, which enables patient mobility, and has dual-sensor technology...RHEA-AIneutral
10/26/22 8:02 AMNasdaq : ABMD Abiomed Creates Patient Assistance Program to Address Disparities in HealthcareAbiomed announces a new program to address healthcare disparities in underserved communities, as new data provides an example of how better access to Impella heart pumps can improve health equity for non-Caucasian cardiovascular patients. “This data about the benefit of Impella-supported procedures for non-Caucasian patients is highly compelling and...RHEA-AIneutral
10/24/22 12:00 PMNasdaq : ABMD managementMedTechVets Appoints Patrice Sutherland, Enterprise Executive Director at Integra LifeScience, as New Board ChairpersonPatrice Sutherland, enterprise executive director at Integra Life Sciences, has been appointed Chairperson of the Board of Directors for MedTechVets, a nonprofit organization that helps military Veterans transition and gain employment at Medical Technology and Life Science companies. A U.S. Army combat Veteran, Sutherland succeeds Derek Herrera and...RHEA-AIvery positive
10/20/22 10:24 AMNasdaq : ABMD Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart FailureAbiomed announces the U.S. Food and Drug Administration has accepted and closed the post-approval study reports related to the pre-market approvals for Impella heart pumps. In total, Abiomed completed five post-approval studies for Impella over the seven years since its initial PMA was received. The totality of Impella data collected in the U.S., Europe and...RHEA-AIpositive
10/17/22 7:58 AMNasdaq : ABMD U.S. FDA Grants 510(k) Clearance for Impella Low Profile SheathThe United States Food and Drug Administration has granted 510 clearance to Abiomed for its Impella Low Profile Sheath. Compared to the existing 14 French sheath used for placement of Impella CP, the new sheath maintains the same inner diameter, but reduces the outer diameter by nearly 2 Fr. “Abiomed’ s Low Profile Sheath is a game changing technological...RHEA-AIvery positive